Cargando…
Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
Androgen receptor (AR) is a validated drug target for all stages of prostate cancer including metastatic castration-resistant prostate cancer (CRPC). All current hormone therapies for CRPC target the C-terminal ligand-binding domain of AR and ultimately all fail with resumed AR transcriptional activ...
Autores principales: | Banuelos, Carmen A., Tavakoli, Iran, Tien, Amy H., Caley, Daniel P., Mawji, Nasrin R., Li, Zhenzhen, Wang, Jun, Yang, Yu Chi, Imamura, Yusuke, Yan, Luping, Wen, Jian Guo, Andersen, Raymond J., Sadar, Marianne D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064002/ https://www.ncbi.nlm.nih.gov/pubmed/27576691 http://dx.doi.org/10.1074/jbc.M116.734475 |
Ejemplares similares
-
SAT022 A Mechanism Of Resistance To Novel Inhibitors Of The N-Terminal Domain Of Androgen Receptor
por: Setiawan, Josie, et al.
Publicado: (2023) -
Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
por: Banuelos, Carmen A., et al.
Publicado: (2014) -
Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor
por: Leung, Jacky K., et al.
Publicado: (2021) -
SAT023 The Role Of Cysteine Residues In The Binding Of Inhibitors Of The N-Terminal Domain Of The Androgen Receptor
por: Deneault, Lauren, et al.
Publicado: (2023) -
The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth
por: Rosati, Rayna, et al.
Publicado: (2016)